These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 31784656)

  • 21. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.
    Gembardt F; Bartaun C; Jarzebska N; Mayoux E; Todorov VT; Hohenstein B; Hugo C
    Am J Physiol Renal Physiol; 2014 Aug; 307(3):F317-25. PubMed ID: 24944269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice.
    Vercalsteren E; Karampatsi D; Buizza C; Nyström T; Klein T; Paul G; Patrone C; Darsalia V
    Cardiovasc Diabetol; 2024 Feb; 23(1):88. PubMed ID: 38424560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SGLT2 inhibitor empagliflozin monotherapy alleviates renal oxidative stress in albino Wistar diabetic rats after myocardial infarction induction.
    Ahmed AS; Mona MM; Abdel-Kareem MA; Elsisy RA
    Biomed Pharmacother; 2021 Jul; 139():111624. PubMed ID: 33915503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the VEGF-A/caveolin-1/PV-1 signaling pathway.
    Locatelli M; Zoja C; Conti S; Cerullo D; Corna D; Rottoli D; Zanchi C; Tomasoni S; Remuzzi G; Benigni A
    J Pathol; 2022 Apr; 256(4):468-479. PubMed ID: 35000230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
    Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
    Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The SGLT2 inhibitor empagliflozin attenuates atherosclerosis progression by inducing autophagy.
    Xu H; Fu J; Tu Q; Shuai Q; Chen Y; Wu F; Cao Z
    J Physiol Biochem; 2024 Feb; 80(1):27-39. PubMed ID: 37792168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
    Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats.
    Shao Q; Meng L; Lee S; Tse G; Gong M; Zhang Z; Zhao J; Zhao Y; Li G; Liu T
    Cardiovasc Diabetol; 2019 Nov; 18(1):165. PubMed ID: 31779619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
    Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
    Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
    Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
    Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes.
    Habibi J; Aroor AR; Sowers JR; Jia G; Hayden MR; Garro M; Barron B; Mayoux E; Rector RS; Whaley-Connell A; DeMarco VG
    Cardiovasc Diabetol; 2017 Jan; 16(1):9. PubMed ID: 28086951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat.
    Hansen HH; Jelsing J; Hansen CF; Hansen G; Vrang N; Mark M; Klein T; Mayoux E
    J Pharmacol Exp Ther; 2014 Sep; 350(3):657-64. PubMed ID: 24993361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice.
    Nakatsu Y; Kokubo H; Bumdelger B; Yoshizumi M; Yamamotoya T; Matsunaga Y; Ueda K; Inoue Y; Inoue MK; Fujishiro M; Kushiyama A; Ono H; Sakoda H; Asano T
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28777298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dosing Time-Dependent Difference in the Suppressive Effect of Empagliflozin on the Development of Mechanical Pain Hypersensitivity in Diabetic Mice.
    Sato A; Yasukochi S; Iwanaka N; Yamauchi T; Tsuruta A; Koyanagi S; Ohdo S
    J Pharmacol Exp Ther; 2024 Jul; 390(2):177-185. PubMed ID: 38458768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of High Fat Feeding and Diabetes on Regression of Atherosclerosis Induced by Low-Density Lipoprotein Receptor Gene Therapy in LDL Receptor-Deficient Mice.
    Willecke F; Yuan C; Oka K; Chan L; Hu Y; Barnhart S; Bornfeldt KE; Goldberg IJ; Fisher EA
    PLoS One; 2015; 10(6):e0128996. PubMed ID: 26046657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease.
    Østergaard MV; Secher T; Christensen M; Salinas CG; Roostalu U; Skytte JL; Rune I; Hansen HH; Jelsing J; Vrang N; Fink LN
    Am J Physiol Renal Physiol; 2021 Aug; 321(2):F149-F161. PubMed ID: 34180715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of empagliflozin and target-organ damage in a novel rodent model of heart failure induced by combined hypertension and diabetes.
    Kräker K; Herse F; Golic M; Reichhart N; Crespo-Garcia S; Strauß O; Grune J; Kintscher U; Ebrahim M; Bader M; Alenina N; Heuser A; Luft FC; Müller DN; Dechend R; Haase N
    Sci Rep; 2020 Aug; 10(1):14061. PubMed ID: 32820187
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance.
    Taberner-Cortés A; Vinué Á; Herrero-Cervera A; Aguilar-Ballester M; Real JT; Burks DJ; Martínez-Hervás S; González-Navarro H
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33287201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Empagliflozin reduces the senescence of cardiac stromal cells and improves cardiac function in a murine model of diabetes.
    Madonna R; Doria V; Minnucci I; Pucci A; Pierdomenico DS; De Caterina R
    J Cell Mol Med; 2020 Nov; 24(21):12331-12340. PubMed ID: 32940423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.